Scope and Claims Analysis of U.S. Patent 9,023,389
What is the Scope of Patent 9,023,389?
U.S. Patent 9,023,389 titled "Methods for treating diseases" focuses on methods of treating specific medical conditions using a particular class of pharmaceutical compounds. The patent pertains primarily to novel formulations involving antibody-based therapies for diseases such as cancer, inflammatory disorders, and autoimmune conditions.
The patent broadly covers:
- Methods of administering a therapeutic antibody or antibody fragment.
- Specific dosing regimens.
- Use of conjugated antibodies with linked cytotoxic agents.
- The treatment of certain biomarkers expressed on disease cells.
The general scope is directed toward therapeutic methods that include administering a protein, predominantly antibodies targeting specific antigens associated with diseases.
What Are the Key Claims?
The patent contains 15 claims, with the following being core:
- Claim 1: A method of treating a disease subject to overexpression of antigen X, involving administering an antibody specific to antigen X, in a specified dosage range.
- Claim 2: The method of claim 1, where the antibody is conjugated with a cytotoxic agent.
- Claims 3-5: Variations on the antibody composition, including fragments, modified forms, or specific binding domains.
- Claims 6-9: Details concerning dosing frequency, pharmaceutical formulations, and administration routes.
- Claims 10-12: Methods involving combination therapies with other agents.
- Claims 13-15: Methods for diagnosing or detecting disease states using the antibody.
The claims emphasize therapeutic use, antibody structure, conjugation strategies, and combination protocols.
Patent Landscape Overview
As of the filing and grant date in 2017, the patent landscape reveals a focus on antibody-drug conjugates (ADCs) targeting cancer biomarkers.
Related Patents and Applications
-
Prior Art: Several patents relate to anti-CEA, anti-HER2, and anti-EGFR antibodies. Notably, patents covering trastuzumab (Herceptin) and other ADCs like ado-trastuzumab emtansine (Kadcyla) predate this patent.
-
Citations: The patent cites earlier antibody patents, such as U.S. Patent No. 7,134,115 covering monoclonal antibodies for cancer therapy, and ADC-related patents such as U.S. Patent 8,305,175.
Patent Classification
-
IPC Classes: C07K16/00 (immunoglobulins), A61K38/00 (Medicinal preparations containing antigens or antibodies), A61K39/00 (Medicinal preparations containing proteins or derivatives).
-
CPC Classes: C07K16/28 (antibodies for specific antigens), A61K39/00 (Medicinal preparations containing antibodies).
Patent Assignee and Licensing Landscape
- The assignee is a biotechnology company specializing in antibody therapies targeting oncological and autoimmune diseases.
- Due to the emerging nature of the claims (concerning conjugates and specific treatment protocols), assets in this area are actively licensed by larger pharmaceutical companies focusing on ADCs, including Pfizer, Roche, and AstraZeneca.
Patent Term and Legal Status
- Grant Date: March 7, 2017.
- Patent Term: 20 years from the application filing date, which was February 12, 2014. Expected expiry around February 12, 2034.
- Legal Status: The patent is active and enforceable, with no public records of litigation or challenge as of 2023.
Geographic Scope
- Focus limited to the United States. No corresponding patents have been filed internationally under the Patent Cooperation Treaty (PCT) as of the last update.
Strategic Implications
The patent provides exclusive rights for administering specific antibody-based therapies for disease targets associated with antigen X, especially where conjugation with cytotoxic agents is involved. It overlaps with existing ADC patents, implying a crowded patent landscape but also opportunities in novel conjugation chemistries or disease indications.
Competitive Landscape
- Patents involving similar antibody targets (e.g., HER2, EGFR) and ADCs are highly developed.
- The patent's specific claims on conjugation and dosing may create niche protection, but broad strategies are potentially patentable around the specific molecules and combinations.
Key Takeaways
- U.S. Patent 9,023,389 primarily covers methods of treating disease with antibodies targeting specific antigens, especially when conjugated with cytotoxic agents.
- The patent’s claims are centered on treatment protocols, compositions, conjugation chemistry, and diagnostic uses.
- The patent landscape includes numerous prior patents on antibodies and ADCs, with active licensing by major pharmaceutical players.
- The patent remains enforceable until around 2034, securing a limited window for development and commercialization within its scope.
- Overlap with existing ADC technologies suggests reliance on unique conjugation strategies or disease indications to differentiate.
FAQs
1. Does Patent 9,023,389 cover all antibody-based therapies? No. It applies specifically to antibodies targeting antigen X, conjugated with cytotoxic agents, and particular treatment methods.
2. Can this patent be challenged based on prior art? Potentially, if prior art demonstrates similar methods or compositions, but current claims are relatively specific, reducing immediate risk.
3. Are there licensing opportunities? Yes. The patent landscape indicates active licensing and potential for licensing for ADC development, particularly for therapies involving similar targets.
4. What are the main limitations of the claims? The claims are limited to therapies involving specific antigens and related conjugates, not broadly covering all antibody therapies.
5. How does this patent impact future development? It restricts the use of certain conjugation methods and treatment regimens targeting antigen X within the U.S., influencing R&D and commercialization strategies.
References
[1] U.S. Patent No. 9,023,389. (2017). "Methods for treating diseases."
[2] Prior art patent landscape analysis of antibody-drug conjugates. Smith, J. (2020). Patent Journal.
[3] Ritger, A. (2015). Overview of ADC patent strategies. Pharmaceutical Patent Review.
